Futura Medical
Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Fut… Read more
Futura Medical - Asset Resilience Ratio
Futura Medical (FUM) has an Asset Resilience Ratio of 23.08% as of December 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2020)
This chart shows how Futura Medical's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Futura Medical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX373.87K | 23.08% |
| Total Liquid Assets | GBX373.87K | 23.08% |
Asset Resilience Insights
- Good Liquidity Position: Futura Medical maintains a healthy 23.08% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Futura Medical Industry Peers by Asset Resilience Ratio
Compare Futura Medical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Futura Medical (2016–2020)
The table below shows the annual Asset Resilience Ratio data for Futura Medical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 23.08% | GBX373.87K | GBX1.62 Million | +15.47pp |
| 2019-12-31 | 7.61% | GBX372.90K | GBX4.90 Million | -24.12pp |
| 2018-12-31 | 31.73% | GBX3.45 Million | GBX10.88 Million | -53.58pp |
| 2017-12-31 | 85.31% | GBX8.19 Million | GBX9.60 Million | -5.51pp |
| 2016-12-31 | 90.82% | GBX12.21 Million | GBX13.44 Million | -- |